董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John L. Lubniewski | 男 | President, Chief Executive Officer and Director | 57 | 144.11万美元 | 29.27 | 2021-07-07 |
| Harry A. George | 男 | Director | 73 | 7.01万美元 | 20.89 | 2021-07-07 |
| Lee McCracken | 男 | Director | 63 | 7.31万美元 | 3.45 | 2021-07-07 |
| Donnie M. Hardison | 男 | Director | 70 | 7.46万美元 | 4.20 | 2021-07-07 |
| Michelle R. Griffin | 女 | Director | 55 | 8.36万美元 | 0.67 | 2021-07-07 |
| Ann F. Hanham | 女 | Chair of Board | 68 | 10.16万美元 | 3.05 | 2021-07-07 |
| James T. LaFrance | 男 | Director | 62 | 7.46万美元 | 4.20 | 2021-07-07 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John L. Lubniewski | 男 | President, Chief Executive Officer and Director | 57 | 144.11万美元 | 29.27 | 2021-07-07 |
| Shaun D. McMeans | 男 | Senior Vice President, Chief Financial Officer, Treasurer and Secretary | 59 | 80.38万美元 | 29.27 | 2021-07-07 |
| Byron T. Lawson | 男 | Senior Vice President and Chief Commercial Officer | 46 | 53.13万美元 | 未持股 | 2021-07-07 |
董事简历
中英对照 | 中文 | 英文- John L. Lubniewski
-
John L. Lubniewski从2011年4月开始担任我司首席商务官。Lubniewski先生从医疗诊断公司Ventana离职加入我司，Ventana是罗氏集团的成员公司及罗氏组织诊断公司（Roche Tissue Diagnostics，简称RTD）的全球总部。罗氏公司于2008年3月收购Ventana，在这之前和之后他担任该公司的多个领导职位达九年。从2010年8月到2011年4月，Lubniewski先生在Ventana担任先进染色平台的高级副总裁和生命周期主管。从2008年1月到2010年8月，Lubniewski先生担任RTD的临床化验部的高级副总裁和生命周期主管，负责管理三个生命周期团队、技术营销与医疗营销，并负责管理全球RTD所有临床化验产品。罗氏公司收购Ventana前，Lubniewski先生在Ventana担任先进染色业务单元的高级副总裁，全球营销与平移诊断业务单元的副总裁，以及研发产品部的总经理。在这些职位上，Lubniewski先生负责管理多项化验与平台开发及商业化工作。加入Ventana前，Lubniewski先生在制造企业美国康宁公司（Corning, Inc.）供职超过十年，担任过多个分部、部门和公司销售与市场职位。Lubniewski先生在克拉逊大学（Clarkson University）获得化学工程理学学士学位。
John L. Lubniewski has served as our President and Chief Executive Officer and as a member of our Board of Directors since April 2019 and before that served as our President and Chief Operating Officer since April 2018. Prior to this, he served as our Senior Vice President and Chief Business Officer since April 2011. Mr. Lubniewski joined us from Ventana Medical Systems, Inc. “Ventana”, a medical diagnostics company and member of the Roche Group, and the global headquarters of Roche Tissue Diagnostics (“RTD”) where he served in leadership roles for nine years both before and after the acquisition of Ventana by Roche Holdings, Inc. (“Roche”) in March 2008. From August 2010 to April 2011 Mr. Lubniewski was Senior Vice President and Lifecycle Leader, Advanced Staining Platforms at Ventana. From January 2008 to August 2010 Mr. Lubniewski served as Senior Vice President and Lifecycle Leader, Clinical Assays at RTD, with responsibility for three lifecycle teams, technical marketing and medical marketing and global accountability for all RTD clinical assay products. Prior to the Roche acquisition of Ventana, Mr. Lubniewski served at Ventana as Senior Vice President, Advanced Staining Business Unit, Vice President Worldwide Marketing and Translational Diagnostic Business Unit, and General Manager, Research Products. In these roles, Mr. Lubniewski was responsible for a variety of assay and platform development and commercialization efforts. Prior to Ventana, Mr. Lubniewski worked for over ten years in a variety of divisional, sector and corporate leadership roles at Corning, Incorporated, a multinational technology company that specializes in specialty glass, ceramics and related materials and technologies including advanced optics, primarily for industrial and scientific applications. Mr. Lubniewski earned a B.S. in Chemical Engineering from Clarkson University. - John L. Lubniewski从2011年4月开始担任我司首席商务官。Lubniewski先生从医疗诊断公司Ventana离职加入我司，Ventana是罗氏集团的成员公司及罗氏组织诊断公司（Roche Tissue Diagnostics，简称RTD）的全球总部。罗氏公司于2008年3月收购Ventana，在这之前和之后他担任该公司的多个领导职位达九年。从2010年8月到2011年4月，Lubniewski先生在Ventana担任先进染色平台的高级副总裁和生命周期主管。从2008年1月到2010年8月，Lubniewski先生担任RTD的临床化验部的高级副总裁和生命周期主管，负责管理三个生命周期团队、技术营销与医疗营销，并负责管理全球RTD所有临床化验产品。罗氏公司收购Ventana前，Lubniewski先生在Ventana担任先进染色业务单元的高级副总裁，全球营销与平移诊断业务单元的副总裁，以及研发产品部的总经理。在这些职位上，Lubniewski先生负责管理多项化验与平台开发及商业化工作。加入Ventana前，Lubniewski先生在制造企业美国康宁公司（Corning, Inc.）供职超过十年，担任过多个分部、部门和公司销售与市场职位。Lubniewski先生在克拉逊大学（Clarkson University）获得化学工程理学学士学位。
- John L. Lubniewski has served as our President and Chief Executive Officer and as a member of our Board of Directors since April 2019 and before that served as our President and Chief Operating Officer since April 2018. Prior to this, he served as our Senior Vice President and Chief Business Officer since April 2011. Mr. Lubniewski joined us from Ventana Medical Systems, Inc. “Ventana”, a medical diagnostics company and member of the Roche Group, and the global headquarters of Roche Tissue Diagnostics (“RTD”) where he served in leadership roles for nine years both before and after the acquisition of Ventana by Roche Holdings, Inc. (“Roche”) in March 2008. From August 2010 to April 2011 Mr. Lubniewski was Senior Vice President and Lifecycle Leader, Advanced Staining Platforms at Ventana. From January 2008 to August 2010 Mr. Lubniewski served as Senior Vice President and Lifecycle Leader, Clinical Assays at RTD, with responsibility for three lifecycle teams, technical marketing and medical marketing and global accountability for all RTD clinical assay products. Prior to the Roche acquisition of Ventana, Mr. Lubniewski served at Ventana as Senior Vice President, Advanced Staining Business Unit, Vice President Worldwide Marketing and Translational Diagnostic Business Unit, and General Manager, Research Products. In these roles, Mr. Lubniewski was responsible for a variety of assay and platform development and commercialization efforts. Prior to Ventana, Mr. Lubniewski worked for over ten years in a variety of divisional, sector and corporate leadership roles at Corning, Incorporated, a multinational technology company that specializes in specialty glass, ceramics and related materials and technologies including advanced optics, primarily for industrial and scientific applications. Mr. Lubniewski earned a B.S. in Chemical Engineering from Clarkson University.
- Harry A. George
-
Harry A. George自2002年起担任Htg Molecular Diagnostics, Inc.董事会成员，并于2007年12月至2013年9月担任Htg Molecular Diagnostics, Inc.董事会主席。George先生于1995年共同创立了风险投资公司Solstice Capital，自成立以来一直担任其管理普通合伙人。George先生于2018年6月至2020年9月担任Radiance Therapeutics的总裁兼首席财务官。他还曾担任多家私营和上市公司的董事会成员，目前在Radiance Therapeutics、MediPacs，Inc.、Post.Bid.Ship，Inc.、Adicyte，Inc.的董事会任职，RxActuator，Inc.和Splash Pharmaceuticals，Inc. George先生还是多个非营利组织的董事会成员，包括南亚利桑那州领导委员会、沙漠天使和初创公司图森，麦奎尔创业中心访客委员会成员，以及Tech Launch Arizona的顾问。在1995年之前，George先生是软件产品公司Interleaf Inc.的联合创始人、董事和财务副总裁。在加入Interleaf之前，George先生是计算机产品公司Kurzweil Computer Products，Inc.的联合创始人、董事兼财务副总裁，Kurzweil Computer Products，Inc.随后被Xerox Imaging Systems收购。George先生获得了A.B.来自Bowdoin College，并于2012年获得亚利桑那大学的名誉科学博士学位。同样在2012年，亚利桑那州生物工业协会授予George先生John McGarrity Bioscience Leader of the Year Award。
Harry A. George has served on Htg Molecular Diagnostics, Inc. Board of Directors since 2002 and served as the chair of Htg Molecular Diagnostics, Inc. Board of Directors from December 2007 until September 2013. Mr. George co-founded Solstice Capital, a venture capital firm, in 1995 and has served as its Managing General Partner since its formation. Mr. George served as President and CFO of Radiance Therapeutics from June 2018 through September 2020. He has also served as a member of the board of directors of a number of private and public companies and is currently serving on the boards of directors of Radiance Therapeutics, Medipacs, Inc., Post.Bid.Ship, Inc., AdiCyte, Inc., RxActuator, Inc. and Splash Pharmaceuticals, Inc. Mr. George is also a member of the boards of directors of several non-profit organizations, including Southern Arizona Leadership Council, Desert Angels and Start-up Tucson, a member of the Board of Visitors of the McGuire Center for Entrepreneurship, and an advisor to Tech Launch Arizona. Prior to 1995 Mr. George was co-founder, Director, and Vice-President of Finance for Interleaf Inc., a software products company. Prior to his time at Interleaf, Mr. George was co-founder, Director and Vice President of Finance of Kurzweil Computer Products, Inc., a computer products company, which subsequently was purchased by Xerox Imaging Systems. Mr. George received an A.B. from Bowdoin College and, in 2012 received an Honorary Doctorate of Science from the University of Arizona. Also in 2012 the Arizona BioIndustry Association conferred upon Mr. George the John McGarrity Bioscience Leader of the Year Award. - Harry A. George自2002年起担任Htg Molecular Diagnostics, Inc.董事会成员，并于2007年12月至2013年9月担任Htg Molecular Diagnostics, Inc.董事会主席。George先生于1995年共同创立了风险投资公司Solstice Capital，自成立以来一直担任其管理普通合伙人。George先生于2018年6月至2020年9月担任Radiance Therapeutics的总裁兼首席财务官。他还曾担任多家私营和上市公司的董事会成员，目前在Radiance Therapeutics、MediPacs，Inc.、Post.Bid.Ship，Inc.、Adicyte，Inc.的董事会任职，RxActuator，Inc.和Splash Pharmaceuticals，Inc. George先生还是多个非营利组织的董事会成员，包括南亚利桑那州领导委员会、沙漠天使和初创公司图森，麦奎尔创业中心访客委员会成员，以及Tech Launch Arizona的顾问。在1995年之前，George先生是软件产品公司Interleaf Inc.的联合创始人、董事和财务副总裁。在加入Interleaf之前，George先生是计算机产品公司Kurzweil Computer Products，Inc.的联合创始人、董事兼财务副总裁，Kurzweil Computer Products，Inc.随后被Xerox Imaging Systems收购。George先生获得了A.B.来自Bowdoin College，并于2012年获得亚利桑那大学的名誉科学博士学位。同样在2012年，亚利桑那州生物工业协会授予George先生John McGarrity Bioscience Leader of the Year Award。
- Harry A. George has served on Htg Molecular Diagnostics, Inc. Board of Directors since 2002 and served as the chair of Htg Molecular Diagnostics, Inc. Board of Directors from December 2007 until September 2013. Mr. George co-founded Solstice Capital, a venture capital firm, in 1995 and has served as its Managing General Partner since its formation. Mr. George served as President and CFO of Radiance Therapeutics from June 2018 through September 2020. He has also served as a member of the board of directors of a number of private and public companies and is currently serving on the boards of directors of Radiance Therapeutics, Medipacs, Inc., Post.Bid.Ship, Inc., AdiCyte, Inc., RxActuator, Inc. and Splash Pharmaceuticals, Inc. Mr. George is also a member of the boards of directors of several non-profit organizations, including Southern Arizona Leadership Council, Desert Angels and Start-up Tucson, a member of the Board of Visitors of the McGuire Center for Entrepreneurship, and an advisor to Tech Launch Arizona. Prior to 1995 Mr. George was co-founder, Director, and Vice-President of Finance for Interleaf Inc., a software products company. Prior to his time at Interleaf, Mr. George was co-founder, Director and Vice President of Finance of Kurzweil Computer Products, Inc., a computer products company, which subsequently was purchased by Xerox Imaging Systems. Mr. George received an A.B. from Bowdoin College and, in 2012 received an Honorary Doctorate of Science from the University of Arizona. Also in 2012 the Arizona BioIndustry Association conferred upon Mr. George the John McGarrity Bioscience Leader of the Year Award.
- Lee McCracken
-
Lee McCracken，2015年10月以来，他担任我们董事会职务。2014年4月以来，他一直担任Gensignia Life Sciences, Inc.的首席执行官。在此之前从2013年4月到2014年3月，他担任McCracken Consulting再生医学与诊断部门的战略与重组顾问。从2012年10月到2013年3月，他担任Pathwork Diagnostics, Inc.（分子诊断公司）的总裁兼首席执行官。从2012年1月至2012年9月，他是McCracken Consulting分子诊断部门的战略顾问。从2004年开始到2011年12月，他是Prometheus Laboratories, Inc.（制药和医疗诊断公司）业务发展公司负责人和顾问。在他职业生涯的早期，他担任过许多行政职务或者在一些生物技术和治疗公司的重要职务，包括GenStar Therapeutics Corporation, CombiChem Inc., Allergan Inc.以及在投资公司 3i Capital and Union Venture。他获得洛杉矶 the University of California的the Anderson School of Management的工商管理硕士学位、the University of Dayton计算机科学硕士学位和Santa Clara University商业学士学位。他目前是一些私营企业包括Gensignia Life Sciences, Inc.的董事。
Lee McCracken has served on our Board of Directors since October 2015. Mr. McCracken currently serves as Entrepreneur in Residence at Thorne HealthTech, a leader in the development of innovative solutions for personalized approaches to health and well-being, and as Chair of the Drawbridge Health, Inc. board of directors, a company focused on enabling personal diagnostic testing. From June 2018 to April 2021 Mr. McCracken served as the Chief Executive Officer of Drawbridge Health, Inc. From May 2016 to May 2017 and from April 2013 to March 2014 he was a strategic and restructuring consultant in the regenerative medicine and diagnostics through his firm, McCracken Consulting. In addition, he was the Chief Executive Officer of Gensignia Life Sciences, Inc., a molecular diagnostics company, from April 2014 through May 2016. Mr. McCracken previously held executive positions or roles with significant responsibility at several biotechnology and therapeutics companies, including Pathwork Diagnostics, Inc., Prometheus Laboratories Inc., GenStar Therapeutics Corporation, CombiChem Inc., and Allergan Inc., as well as at the investment companies, 3i Capital and Union Venture. Mr. McCracken received his M.B.A. from the Anderson School of Management at the University of California, Los Angeles, his Master of Computer Science MCS from the University of Dayton, and his B.S. in Commerce from Santa Clara University. - Lee McCracken，2015年10月以来，他担任我们董事会职务。2014年4月以来，他一直担任Gensignia Life Sciences, Inc.的首席执行官。在此之前从2013年4月到2014年3月，他担任McCracken Consulting再生医学与诊断部门的战略与重组顾问。从2012年10月到2013年3月，他担任Pathwork Diagnostics, Inc.（分子诊断公司）的总裁兼首席执行官。从2012年1月至2012年9月，他是McCracken Consulting分子诊断部门的战略顾问。从2004年开始到2011年12月，他是Prometheus Laboratories, Inc.（制药和医疗诊断公司）业务发展公司负责人和顾问。在他职业生涯的早期，他担任过许多行政职务或者在一些生物技术和治疗公司的重要职务，包括GenStar Therapeutics Corporation, CombiChem Inc., Allergan Inc.以及在投资公司 3i Capital and Union Venture。他获得洛杉矶 the University of California的the Anderson School of Management的工商管理硕士学位、the University of Dayton计算机科学硕士学位和Santa Clara University商业学士学位。他目前是一些私营企业包括Gensignia Life Sciences, Inc.的董事。
- Lee McCracken has served on our Board of Directors since October 2015. Mr. McCracken currently serves as Entrepreneur in Residence at Thorne HealthTech, a leader in the development of innovative solutions for personalized approaches to health and well-being, and as Chair of the Drawbridge Health, Inc. board of directors, a company focused on enabling personal diagnostic testing. From June 2018 to April 2021 Mr. McCracken served as the Chief Executive Officer of Drawbridge Health, Inc. From May 2016 to May 2017 and from April 2013 to March 2014 he was a strategic and restructuring consultant in the regenerative medicine and diagnostics through his firm, McCracken Consulting. In addition, he was the Chief Executive Officer of Gensignia Life Sciences, Inc., a molecular diagnostics company, from April 2014 through May 2016. Mr. McCracken previously held executive positions or roles with significant responsibility at several biotechnology and therapeutics companies, including Pathwork Diagnostics, Inc., Prometheus Laboratories Inc., GenStar Therapeutics Corporation, CombiChem Inc., and Allergan Inc., as well as at the investment companies, 3i Capital and Union Venture. Mr. McCracken received his M.B.A. from the Anderson School of Management at the University of California, Los Angeles, his Master of Computer Science MCS from the University of Dayton, and his B.S. in Commerce from Santa Clara University.
- Donnie M. Hardison
-
Donnie M. Hardison自2016年5月起在我们的董事会任职。2016年4月，他成立并担任DMH Consulting（一家管理咨询公司）的独资经营者。 2010年4月至2016年3月，Hardison先生是Good Start Genetics公司（一家医疗器械公司）的总裁兼首席执行官。在此之前的20多年里，Hardison先生在Laboratory Corporation of America（一家临床实验室公司），Exact Sciences Corporation（一家分子诊断公司）OnTarget，Inc。（一家销售和营销咨询公司）Quest Diagnostics Inc.（一家临床实验室公司），SmithKline Beecham Corporation（一家制药公司）和其他公司担任过多个执行和高级管理职位。他目前是Seventh Sense Biosystems, Inc.（一家私人医疗技术公司）的董事会成员，曾在多家其他私营公司（包括Good Start Genetics）担任董事会成员。2000年5月至2007年8月，他还担任Exact Science Corporation NASDAQ：EXAS的董事会成员。Hardison先生获得University of North Carolina政治科学的文学士学位。
Donnie M. Hardison,independent non-executive director of our Company, has served on our Board of Directors since October 2021. Since February 2021 he has been the sole proprietor of DMH Consulting, a management consulting firm that he founded and previously operated from April 2016 to January 2017.He was most recently the President and Chief Executive Officer, and served on the board of directors, of Biotheranostics, Inc., a molecular diagnostic company focused on oncology, from February 2017 until it was acquired by Hologic, Inc. in February 2021. From April 2010 to March 2016 Mr. Hardison was the President and Chief Executive Officer of Good Start Genetics, a molecular genetic testing and information company. For more than 20 years prior to that, Mr. Hardison held various executive and senior management positions at companies including Laboratory Corporation of America LabCorp a clinical laboratory company, Exact Sciences Corporation, a molecular diagnostics company, OnTarget, Inc., a sales and marketing consulting company, Quest Diagnostics Inc., a clinical laboratory company, SmithKline Beecham Corporation, a pharmaceutical company, and others. He served on the board of directors of Exact Sciences Corporation (Nasdaq: EXAS) from May 2000 through its initial public offering in February 2001 until August 2007. Mr. Hardison received his Bachelor of Arts degree, in political science, from the University of North Carolina, Chapel Hill. - Donnie M. Hardison自2016年5月起在我们的董事会任职。2016年4月，他成立并担任DMH Consulting（一家管理咨询公司）的独资经营者。 2010年4月至2016年3月，Hardison先生是Good Start Genetics公司（一家医疗器械公司）的总裁兼首席执行官。在此之前的20多年里，Hardison先生在Laboratory Corporation of America（一家临床实验室公司），Exact Sciences Corporation（一家分子诊断公司）OnTarget，Inc。（一家销售和营销咨询公司）Quest Diagnostics Inc.（一家临床实验室公司），SmithKline Beecham Corporation（一家制药公司）和其他公司担任过多个执行和高级管理职位。他目前是Seventh Sense Biosystems, Inc.（一家私人医疗技术公司）的董事会成员，曾在多家其他私营公司（包括Good Start Genetics）担任董事会成员。2000年5月至2007年8月，他还担任Exact Science Corporation NASDAQ：EXAS的董事会成员。Hardison先生获得University of North Carolina政治科学的文学士学位。
- Donnie M. Hardison,independent non-executive director of our Company, has served on our Board of Directors since October 2021. Since February 2021 he has been the sole proprietor of DMH Consulting, a management consulting firm that he founded and previously operated from April 2016 to January 2017.He was most recently the President and Chief Executive Officer, and served on the board of directors, of Biotheranostics, Inc., a molecular diagnostic company focused on oncology, from February 2017 until it was acquired by Hologic, Inc. in February 2021. From April 2010 to March 2016 Mr. Hardison was the President and Chief Executive Officer of Good Start Genetics, a molecular genetic testing and information company. For more than 20 years prior to that, Mr. Hardison held various executive and senior management positions at companies including Laboratory Corporation of America LabCorp a clinical laboratory company, Exact Sciences Corporation, a molecular diagnostics company, OnTarget, Inc., a sales and marketing consulting company, Quest Diagnostics Inc., a clinical laboratory company, SmithKline Beecham Corporation, a pharmaceutical company, and others. He served on the board of directors of Exact Sciences Corporation (Nasdaq: EXAS) from May 2000 through its initial public offering in February 2001 until August 2007. Mr. Hardison received his Bachelor of Arts degree, in political science, from the University of North Carolina, Chapel Hill.
- Michelle R. Griffin
-
MichelleR.Griffin自2018年8月以来一直担任我们的董事会成员。Griffin女士目前担任Acer Therapeutics，Inc.的董事会成员和审计委员会主席。纳斯达克股票代码:ACER和Adaptive Biotechnologies Corp（NASDAQ:ADPT）。她还曾于2016年至2018年担任Phaserx，Inc.（NASDAQ:PZRX）和Sonus Pharmaceuticals的董事会成员和审计委员会主席，Oncogenex Pharmaceuticals Inc.（NASDAQ:OGXI）和Sonus Pharmaceuticals，Inc.（纳斯达克股票代码:SNUS）从2004年到2008年担任Universal Cells的董事会主席，Inc.从2017年到2018年被Astellas Pharma Inc.收购；2014年至2018年担任Virginia Mason Health System和Virginia Mason Medical Center的董事会成员；以及从2012年到2014年担任Polynoma LLC董事会成员。Griffin从2011年到2013年担任Oncogenex的执行Vice President、运营和首席财务官，曾担任Trubion Pharmaceuticals的代理首席执行官、高级副总裁和首席运营官，2009年至2010年被收购，2006年至2009年担任首席财务官；2005年至2006年担任Dendreon Corp.的高级副总裁和首席财务官。Griffin女士于1994年在Corixa Corp.（纳斯达克市场代码:CRXA）开始了她在生物制药行业的职业生涯，从1997年该公司首次公开募股到2005年Corixa被GlaxoSmithKline plc收购，她一直担任该公司的首席财务官。她在西雅图大学（Seattle University）获得会计学研究生证书和工商管理硕士学位，在乔治梅森大学（George Mason University）获得统计学和营销学学士学位，并通过了注册会计师考试。
Michelle R. Griffin has served on our Board of Directors since August 2018. Ms. Griffin currently serves as a member of the board of directors and chair of the audit committee for Acer Therapeutics, Inc. Nasdaq: ACER, Adaptive Biotechnologies Corp (Nasdaq: ADPT) and Chinook Therapeutics, Inc. (Nasdaq: KDNY). She has also served on the board of directors and as audit committee chair for PhaseRx, Inc. (Nasdaq: PZRX) from 2016 to 2018 OncoGenex Pharmaceuticals Inc. (Nasdaq: OGXI) from 2008 to 2011 and Sonus Pharmaceuticals, Inc. (Nasdaq: SNUS) from 2004 to 2008. Ms. Griffin served as executive vice president, operations, and chief financial officer at OncoGenex from 2011 to 2013; served as acting chief executive, senior vice president and chief operating officer at Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) from 2009 until its acquisition in 2010 and as its chief financial officer from 2006 to 2009; and served as senior vice president and chief financial officer of Dendreon Corp. (Nasdaq: DNRD) from 2005 to 2006. Ms. Griffin began her career in the biopharmaceuticals industry in 1994 at Corixa Corp. (Nasdaq: CRXA) and served as its chief financial officer from its IPO in 1997 until 2005 when Corixa was acquired by GlaxoSmithKline plc. She received a post‐graduate certificate in accounting and an MBA from Seattle University, a B.S. in statistics and marketing from George Mason University and has passed the certified public accountant exam. - MichelleR.Griffin自2018年8月以来一直担任我们的董事会成员。Griffin女士目前担任Acer Therapeutics，Inc.的董事会成员和审计委员会主席。纳斯达克股票代码:ACER和Adaptive Biotechnologies Corp（NASDAQ:ADPT）。她还曾于2016年至2018年担任Phaserx，Inc.（NASDAQ:PZRX）和Sonus Pharmaceuticals的董事会成员和审计委员会主席，Oncogenex Pharmaceuticals Inc.（NASDAQ:OGXI）和Sonus Pharmaceuticals，Inc.（纳斯达克股票代码:SNUS）从2004年到2008年担任Universal Cells的董事会主席，Inc.从2017年到2018年被Astellas Pharma Inc.收购；2014年至2018年担任Virginia Mason Health System和Virginia Mason Medical Center的董事会成员；以及从2012年到2014年担任Polynoma LLC董事会成员。Griffin从2011年到2013年担任Oncogenex的执行Vice President、运营和首席财务官，曾担任Trubion Pharmaceuticals的代理首席执行官、高级副总裁和首席运营官，2009年至2010年被收购，2006年至2009年担任首席财务官；2005年至2006年担任Dendreon Corp.的高级副总裁和首席财务官。Griffin女士于1994年在Corixa Corp.（纳斯达克市场代码:CRXA）开始了她在生物制药行业的职业生涯，从1997年该公司首次公开募股到2005年Corixa被GlaxoSmithKline plc收购，她一直担任该公司的首席财务官。她在西雅图大学（Seattle University）获得会计学研究生证书和工商管理硕士学位，在乔治梅森大学（George Mason University）获得统计学和营销学学士学位，并通过了注册会计师考试。
- Michelle R. Griffin has served on our Board of Directors since August 2018. Ms. Griffin currently serves as a member of the board of directors and chair of the audit committee for Acer Therapeutics, Inc. Nasdaq: ACER, Adaptive Biotechnologies Corp (Nasdaq: ADPT) and Chinook Therapeutics, Inc. (Nasdaq: KDNY). She has also served on the board of directors and as audit committee chair for PhaseRx, Inc. (Nasdaq: PZRX) from 2016 to 2018 OncoGenex Pharmaceuticals Inc. (Nasdaq: OGXI) from 2008 to 2011 and Sonus Pharmaceuticals, Inc. (Nasdaq: SNUS) from 2004 to 2008. Ms. Griffin served as executive vice president, operations, and chief financial officer at OncoGenex from 2011 to 2013; served as acting chief executive, senior vice president and chief operating officer at Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) from 2009 until its acquisition in 2010 and as its chief financial officer from 2006 to 2009; and served as senior vice president and chief financial officer of Dendreon Corp. (Nasdaq: DNRD) from 2005 to 2006. Ms. Griffin began her career in the biopharmaceuticals industry in 1994 at Corixa Corp. (Nasdaq: CRXA) and served as its chief financial officer from its IPO in 1997 until 2005 when Corixa was acquired by GlaxoSmithKline plc. She received a post‐graduate certificate in accounting and an MBA from Seattle University, a B.S. in statistics and marketing from George Mason University and has passed the certified public accountant exam.
- Ann F. Hanham
-
Ann F. Hanham，2004年11月起，成为董事会成员；2000年2月，加入Burrill & Company（风险资本和商业银行公司）；2002年至2013年，担任行政董事；2001年5月至2006年9月，在BioMimetic Therapeutics（生物制药公司）担任董事；2009年3月至2011年4月，是Biotie Therapies（药物开发公司）董事；2005年9月至2006年8月，是Targacept（生物制药公司）董事。获有多伦多大学学士学位、西蒙弗雷泽大学硕士学位以及英属哥伦比亚大学医学博士学位。
Ann F. Hanham,has served as a member of Scynexis, Inc. Board since December 2008. Prior to becoming a Founding Partner and Managing Director of BAR Capital Management, a privately-held life-sciences venture capital fund, in December 2013, she was a General Partner with Burrill & Company, a life sciences venture capital firm from 2000 to 2013. From 1998 to 2000, Dr. Hanham was a co-founder and Vice President of Clinical & Regulatory Affairs at InterMune, Inc. From 1995 to 1998, she served as the Senior Director for Oncology Product Development at Otsuka Pharmaceuticals and from 1991 to 1995 as the Medical Director for Celtrix Pharmaceuticals. From 1988 to 1991, Dr. Hanham worked for Becton Dickinson in both regulatory and clinical affairs for the monoclonal antibody program, and from 1984 to 1988 as a regulatory toxicologist with the Health Protection Branch of Health and Welfare Canada. She serves as a member of the board of directors of HTG Molecular Diagnostics Inc. (Nasdaq: HTGM) and previously served as a member of the boards of directors of Acusphere Inc. (OTCMKTS: ACUS), Biomimetic Therapeutics Inc. (Nasdaq: BMTI), Biotie Therapies Corp. (Nordic List: BTH1V), Immunicon Corp. (Nasdaq: IMMC), Targacept Inc. (Nasdaq: TRGT), TLC (GreTai Sec M: 1452:TT) and Endocyte, Inc. (Nasdaq: ECYT). Dr. Hanham holds a Ph.D. from the University of British Columbia, an MSc from Simon Fraser University, and a BSc from the University of Toronto. She was also Board Certified in Toxicology in 1986. - Ann F. Hanham，2004年11月起，成为董事会成员；2000年2月，加入Burrill & Company（风险资本和商业银行公司）；2002年至2013年，担任行政董事；2001年5月至2006年9月，在BioMimetic Therapeutics（生物制药公司）担任董事；2009年3月至2011年4月，是Biotie Therapies（药物开发公司）董事；2005年9月至2006年8月，是Targacept（生物制药公司）董事。获有多伦多大学学士学位、西蒙弗雷泽大学硕士学位以及英属哥伦比亚大学医学博士学位。
- Ann F. Hanham,has served as a member of Scynexis, Inc. Board since December 2008. Prior to becoming a Founding Partner and Managing Director of BAR Capital Management, a privately-held life-sciences venture capital fund, in December 2013, she was a General Partner with Burrill & Company, a life sciences venture capital firm from 2000 to 2013. From 1998 to 2000, Dr. Hanham was a co-founder and Vice President of Clinical & Regulatory Affairs at InterMune, Inc. From 1995 to 1998, she served as the Senior Director for Oncology Product Development at Otsuka Pharmaceuticals and from 1991 to 1995 as the Medical Director for Celtrix Pharmaceuticals. From 1988 to 1991, Dr. Hanham worked for Becton Dickinson in both regulatory and clinical affairs for the monoclonal antibody program, and from 1984 to 1988 as a regulatory toxicologist with the Health Protection Branch of Health and Welfare Canada. She serves as a member of the board of directors of HTG Molecular Diagnostics Inc. (Nasdaq: HTGM) and previously served as a member of the boards of directors of Acusphere Inc. (OTCMKTS: ACUS), Biomimetic Therapeutics Inc. (Nasdaq: BMTI), Biotie Therapies Corp. (Nordic List: BTH1V), Immunicon Corp. (Nasdaq: IMMC), Targacept Inc. (Nasdaq: TRGT), TLC (GreTai Sec M: 1452:TT) and Endocyte, Inc. (Nasdaq: ECYT). Dr. Hanham holds a Ph.D. from the University of British Columbia, an MSc from Simon Fraser University, and a BSc from the University of Toronto. She was also Board Certified in Toxicology in 1986.
- James T. LaFrance
-
James T. LaFrance，他于2013年12月当选为我们的董事，还当选我们的董事会主席。他于2014年4月23日成为我们的总裁兼首席执行官。他拥有近30年的诊断行业工作经验。最近，他曾担任GE Healthcare公司（医疗技术供应商）的Omnyx公司的数字病理主管，以及代理首席执行官。此前，他曾担任Ventana Medical Systems公司（目前是Roche Tissue Diagnostics公司，组织的诊断解决方案供应商）的多种商业、战略营销和业务发展的领导职务，包括北美和国际商业组织的总经理。任职Ventana公司之前，他曾担任Bayer Diagnostics公司的战略营销和业务发展的领导职务。从2010年到2011年，他曾是Mitomics公司的董事会成员。他持有the University of Connecticut的经济学学士学位，以及the University of Notre Dame的工商管理硕士学位。
James T. LaFrance has served on our Board of Directors since December 2015. Mr. LaFrance has over thirty-five years of diagnostic industry experience, and has worked since January 2015 as a sales, marketing, strategy development and commercial operational management consultant for LaFrance Consulting LLC, a consulting firm he founded. He currently serves on two additional boards, Aspira Women’s Health Nasdaq: AWH; formerly VRMS as Chairman; and as an independent director of privately held Personal Genome Diagnostics. He served as interim Chief Executive Officer of Vermillion, Inc. (Nasdaq: VRML) in 2014 and as Chief Executive Officer for Omnyx, LLC, a UPMC/GE Healthcare joint venture from 2012 to 2013. Mr. LaFrance held a series of senior management roles at Ventana Medical Systems (now Roche Tissue Diagnostics), including general management of the North American and international commercial operations. Prior to working for Ventana, Mr. LaFrance served in leadership roles in strategic marketing and business development at Bayer Diagnostics. He earned a Bachelor of Arts degree in Economics from the University of Connecticut and holds a Master’s in Business Administration from the University of Notre Dame. - James T. LaFrance，他于2013年12月当选为我们的董事，还当选我们的董事会主席。他于2014年4月23日成为我们的总裁兼首席执行官。他拥有近30年的诊断行业工作经验。最近，他曾担任GE Healthcare公司（医疗技术供应商）的Omnyx公司的数字病理主管，以及代理首席执行官。此前，他曾担任Ventana Medical Systems公司（目前是Roche Tissue Diagnostics公司，组织的诊断解决方案供应商）的多种商业、战略营销和业务发展的领导职务，包括北美和国际商业组织的总经理。任职Ventana公司之前，他曾担任Bayer Diagnostics公司的战略营销和业务发展的领导职务。从2010年到2011年，他曾是Mitomics公司的董事会成员。他持有the University of Connecticut的经济学学士学位，以及the University of Notre Dame的工商管理硕士学位。
- James T. LaFrance has served on our Board of Directors since December 2015. Mr. LaFrance has over thirty-five years of diagnostic industry experience, and has worked since January 2015 as a sales, marketing, strategy development and commercial operational management consultant for LaFrance Consulting LLC, a consulting firm he founded. He currently serves on two additional boards, Aspira Women’s Health Nasdaq: AWH; formerly VRMS as Chairman; and as an independent director of privately held Personal Genome Diagnostics. He served as interim Chief Executive Officer of Vermillion, Inc. (Nasdaq: VRML) in 2014 and as Chief Executive Officer for Omnyx, LLC, a UPMC/GE Healthcare joint venture from 2012 to 2013. Mr. LaFrance held a series of senior management roles at Ventana Medical Systems (now Roche Tissue Diagnostics), including general management of the North American and international commercial operations. Prior to working for Ventana, Mr. LaFrance served in leadership roles in strategic marketing and business development at Bayer Diagnostics. He earned a Bachelor of Arts degree in Economics from the University of Connecticut and holds a Master’s in Business Administration from the University of Notre Dame.
高管简历
中英对照 | 中文 | 英文- John L. Lubniewski
John L. Lubniewski从2011年4月开始担任我司首席商务官。Lubniewski先生从医疗诊断公司Ventana离职加入我司，Ventana是罗氏集团的成员公司及罗氏组织诊断公司（Roche Tissue Diagnostics，简称RTD）的全球总部。罗氏公司于2008年3月收购Ventana，在这之前和之后他担任该公司的多个领导职位达九年。从2010年8月到2011年4月，Lubniewski先生在Ventana担任先进染色平台的高级副总裁和生命周期主管。从2008年1月到2010年8月，Lubniewski先生担任RTD的临床化验部的高级副总裁和生命周期主管，负责管理三个生命周期团队、技术营销与医疗营销，并负责管理全球RTD所有临床化验产品。罗氏公司收购Ventana前，Lubniewski先生在Ventana担任先进染色业务单元的高级副总裁，全球营销与平移诊断业务单元的副总裁，以及研发产品部的总经理。在这些职位上，Lubniewski先生负责管理多项化验与平台开发及商业化工作。加入Ventana前，Lubniewski先生在制造企业美国康宁公司（Corning, Inc.）供职超过十年，担任过多个分部、部门和公司销售与市场职位。Lubniewski先生在克拉逊大学（Clarkson University）获得化学工程理学学士学位。
John L. Lubniewski has served as our President and Chief Executive Officer and as a member of our Board of Directors since April 2019 and before that served as our President and Chief Operating Officer since April 2018. Prior to this, he served as our Senior Vice President and Chief Business Officer since April 2011. Mr. Lubniewski joined us from Ventana Medical Systems, Inc. “Ventana”, a medical diagnostics company and member of the Roche Group, and the global headquarters of Roche Tissue Diagnostics (“RTD”) where he served in leadership roles for nine years both before and after the acquisition of Ventana by Roche Holdings, Inc. (“Roche”) in March 2008. From August 2010 to April 2011 Mr. Lubniewski was Senior Vice President and Lifecycle Leader, Advanced Staining Platforms at Ventana. From January 2008 to August 2010 Mr. Lubniewski served as Senior Vice President and Lifecycle Leader, Clinical Assays at RTD, with responsibility for three lifecycle teams, technical marketing and medical marketing and global accountability for all RTD clinical assay products. Prior to the Roche acquisition of Ventana, Mr. Lubniewski served at Ventana as Senior Vice President, Advanced Staining Business Unit, Vice President Worldwide Marketing and Translational Diagnostic Business Unit, and General Manager, Research Products. In these roles, Mr. Lubniewski was responsible for a variety of assay and platform development and commercialization efforts. Prior to Ventana, Mr. Lubniewski worked for over ten years in a variety of divisional, sector and corporate leadership roles at Corning, Incorporated, a multinational technology company that specializes in specialty glass, ceramics and related materials and technologies including advanced optics, primarily for industrial and scientific applications. Mr. Lubniewski earned a B.S. in Chemical Engineering from Clarkson University.- John L. Lubniewski从2011年4月开始担任我司首席商务官。Lubniewski先生从医疗诊断公司Ventana离职加入我司，Ventana是罗氏集团的成员公司及罗氏组织诊断公司（Roche Tissue Diagnostics，简称RTD）的全球总部。罗氏公司于2008年3月收购Ventana，在这之前和之后他担任该公司的多个领导职位达九年。从2010年8月到2011年4月，Lubniewski先生在Ventana担任先进染色平台的高级副总裁和生命周期主管。从2008年1月到2010年8月，Lubniewski先生担任RTD的临床化验部的高级副总裁和生命周期主管，负责管理三个生命周期团队、技术营销与医疗营销，并负责管理全球RTD所有临床化验产品。罗氏公司收购Ventana前，Lubniewski先生在Ventana担任先进染色业务单元的高级副总裁，全球营销与平移诊断业务单元的副总裁，以及研发产品部的总经理。在这些职位上，Lubniewski先生负责管理多项化验与平台开发及商业化工作。加入Ventana前，Lubniewski先生在制造企业美国康宁公司（Corning, Inc.）供职超过十年，担任过多个分部、部门和公司销售与市场职位。Lubniewski先生在克拉逊大学（Clarkson University）获得化学工程理学学士学位。
- John L. Lubniewski has served as our President and Chief Executive Officer and as a member of our Board of Directors since April 2019 and before that served as our President and Chief Operating Officer since April 2018. Prior to this, he served as our Senior Vice President and Chief Business Officer since April 2011. Mr. Lubniewski joined us from Ventana Medical Systems, Inc. “Ventana”, a medical diagnostics company and member of the Roche Group, and the global headquarters of Roche Tissue Diagnostics (“RTD”) where he served in leadership roles for nine years both before and after the acquisition of Ventana by Roche Holdings, Inc. (“Roche”) in March 2008. From August 2010 to April 2011 Mr. Lubniewski was Senior Vice President and Lifecycle Leader, Advanced Staining Platforms at Ventana. From January 2008 to August 2010 Mr. Lubniewski served as Senior Vice President and Lifecycle Leader, Clinical Assays at RTD, with responsibility for three lifecycle teams, technical marketing and medical marketing and global accountability for all RTD clinical assay products. Prior to the Roche acquisition of Ventana, Mr. Lubniewski served at Ventana as Senior Vice President, Advanced Staining Business Unit, Vice President Worldwide Marketing and Translational Diagnostic Business Unit, and General Manager, Research Products. In these roles, Mr. Lubniewski was responsible for a variety of assay and platform development and commercialization efforts. Prior to Ventana, Mr. Lubniewski worked for over ten years in a variety of divisional, sector and corporate leadership roles at Corning, Incorporated, a multinational technology company that specializes in specialty glass, ceramics and related materials and technologies including advanced optics, primarily for industrial and scientific applications. Mr. Lubniewski earned a B.S. in Chemical Engineering from Clarkson University.
- Shaun D. McMeans
Shaun D. McMeans从2014年4月开始担任我司研究与产品开发部的高级副总裁。Dr. Roche从医疗诊断公司Ventana离职加入我司，Ventana是罗氏集团的成员公司及RTD的全球总部，他在该公司任职达12年，并担任过多个职责递增的多个职位，包括从2009年8月到2014年4月，担任生物标记策略、平移诊断部的副总裁；从2007年3月到2009年7月，担任化验开发及临床研究部的副总裁。在这些职位上，Roche博士负责在开发目标癌症疗法时与制药合作伙伴对接，并促进生物标记转变为搭配诊断。他还领导了试剂产品开发并向市场推出超过30项的试管内诊断产品，包括美国食品与药物管理局批准的干细胞因子与人类表皮生长因子受体检测。在Ventana任职前，Roche博士在医疗研究小组罗彻斯特梅奥医学中心（Mayo Clinic Rochester）任职，他在那里担任担任免疫组织化学实验室的主任， 并担任实验室医学和病理学的副教授。Roche博士是超过125篇期刊论文的合著者，并是多项专利申请及两项已颁发美国专利的发明者。Roche博士在南加利福尼亚大学（University of Southern California）获得生物学理学学士学位；在南加利福尼亚大学（University of Southern California）医学院获得实验病理学的博士学位。
Shaun D. McMeans has served as our Senior Vice President and Chief Financial Officer since February 2018 and as our Vice President and Chief Financial Officer since February 2012. Prior to joining us, Mr. McMeans was Vice President - Finance of Securaplane Technologies, Inc., a product supply company and division of Meggitt PLC, an aerospace, defense and energy conglomerate, from May 2011 to February 2012. Mr. McMeans was a financial consultant from February 2008 to April 2011 working both in an individual capacity and as a partner for Tatum LLC, a consulting company. Prior to February 2008 Mr. McMeans was Chief Financial Officer for The Long Companies, a full service residential and commercial real estate division of Berkshire Hathaway, Inc. Mr. McMeans also worked for over five years at LXU Healthcare, Inc., a manufacturer and distributor of specialty surgical equipment, as Controller and then Chief Financial and Operating Officer. In his early career, Mr. McMeans worked in roles of increasing responsibility, including Director of Finance, for Burnham Holdings, Inc., formerly Burnham Corporation, a manufacturer and distributor of residential and commercial hydronic heating equipment. Mr. McMeans received his B.S. in Accounting from The Pennsylvania State University.- Shaun D. McMeans从2014年4月开始担任我司研究与产品开发部的高级副总裁。Dr. Roche从医疗诊断公司Ventana离职加入我司，Ventana是罗氏集团的成员公司及RTD的全球总部，他在该公司任职达12年，并担任过多个职责递增的多个职位，包括从2009年8月到2014年4月，担任生物标记策略、平移诊断部的副总裁；从2007年3月到2009年7月，担任化验开发及临床研究部的副总裁。在这些职位上，Roche博士负责在开发目标癌症疗法时与制药合作伙伴对接，并促进生物标记转变为搭配诊断。他还领导了试剂产品开发并向市场推出超过30项的试管内诊断产品，包括美国食品与药物管理局批准的干细胞因子与人类表皮生长因子受体检测。在Ventana任职前，Roche博士在医疗研究小组罗彻斯特梅奥医学中心（Mayo Clinic Rochester）任职，他在那里担任担任免疫组织化学实验室的主任， 并担任实验室医学和病理学的副教授。Roche博士是超过125篇期刊论文的合著者，并是多项专利申请及两项已颁发美国专利的发明者。Roche博士在南加利福尼亚大学（University of Southern California）获得生物学理学学士学位；在南加利福尼亚大学（University of Southern California）医学院获得实验病理学的博士学位。
- Shaun D. McMeans has served as our Senior Vice President and Chief Financial Officer since February 2018 and as our Vice President and Chief Financial Officer since February 2012. Prior to joining us, Mr. McMeans was Vice President - Finance of Securaplane Technologies, Inc., a product supply company and division of Meggitt PLC, an aerospace, defense and energy conglomerate, from May 2011 to February 2012. Mr. McMeans was a financial consultant from February 2008 to April 2011 working both in an individual capacity and as a partner for Tatum LLC, a consulting company. Prior to February 2008 Mr. McMeans was Chief Financial Officer for The Long Companies, a full service residential and commercial real estate division of Berkshire Hathaway, Inc. Mr. McMeans also worked for over five years at LXU Healthcare, Inc., a manufacturer and distributor of specialty surgical equipment, as Controller and then Chief Financial and Operating Officer. In his early career, Mr. McMeans worked in roles of increasing responsibility, including Director of Finance, for Burnham Holdings, Inc., formerly Burnham Corporation, a manufacturer and distributor of residential and commercial hydronic heating equipment. Mr. McMeans received his B.S. in Accounting from The Pennsylvania State University.
- Byron T. Lawson
ByronT.Lawson于2020年1月担任我们的高级副总裁兼首席商务官，此前自2018年1月起担任我们的高级副总裁，制药业务部门。在此之前，他从2012年10月开始担任我司商业期权高级总监。加入我们之前，他曾任职Ventana公司近15年，在那里他曾担任多种职务，并在北美商业组织中承担越来越多的责任。他也曾任职美国空军（the United States Air Force）近10年，介于现役和预备役之间，担任注册组织学技术员。
Byron T. Lawson has served as our Senior Vice President and Chief Commercial Officer since January 2020 and previously served as our Senior Vice President, Pharma Business Unit since January 2018. Prior to this, he served as our Vice President, Commercial Operations since April 2016 and Senior Director, Commercial Options since October 2012. Mr. Lawson joined us from Ventana, where he worked for nearly 15 years and served in a variety of roles with increasing responsibility in the North American commercial organization. He also served in the United States Air Force for nearly 10 years between Active and Reserve Duty as a certified Histology Technician.- ByronT.Lawson于2020年1月担任我们的高级副总裁兼首席商务官，此前自2018年1月起担任我们的高级副总裁，制药业务部门。在此之前，他从2012年10月开始担任我司商业期权高级总监。加入我们之前，他曾任职Ventana公司近15年，在那里他曾担任多种职务，并在北美商业组织中承担越来越多的责任。他也曾任职美国空军（the United States Air Force）近10年，介于现役和预备役之间，担任注册组织学技术员。
- Byron T. Lawson has served as our Senior Vice President and Chief Commercial Officer since January 2020 and previously served as our Senior Vice President, Pharma Business Unit since January 2018. Prior to this, he served as our Vice President, Commercial Operations since April 2016 and Senior Director, Commercial Options since October 2012. Mr. Lawson joined us from Ventana, where he worked for nearly 15 years and served in a variety of roles with increasing responsibility in the North American commercial organization. He also served in the United States Air Force for nearly 10 years between Active and Reserve Duty as a certified Histology Technician.